-
-
-
-
-
-
-
PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
-
-
-
-
-
-
-
PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
-
-
-
-
-
-
-
Astellas Completes Acquisition of Propella Therapeutics
-
-
-
-
-
-
-
Astellas Enters into Definitive Agreement to Acquire Iveric Bio
-
-
-
-
-
-
-
Astellas and Minovia Therapeutics Announce Strategic Collaboration for Novel Mitochondrial Cell Therapy Programs
-
-
-
-
-
-
-
U.S. FDA Grants Fast Track Designation to Astellas for the Development of ASP1128 for Patients at Risk for Acute Kidney Injury
-
-
-
-
-
-
-
Astellas Completes Acquisition of Mitobridge, Inc.
-
1,158,058 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

